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144Evaluating the Impact of Uveitis on Visual Field
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PEARSE A. KEANE, ALASTAIR K. DENNISTON, AND DAVID P. CRABB PURPOSE: To compare rates of visual field (VF) loss in
uveitis patients with glaucoma against patients with pri-
mary open-angle glaucoma (POAG) and explore the asso-
ciation between intraocular pressure (IOP) and rate of
VF loss.
 DESIGN: Retrospective cohort study.
 METHODS: Anonymized VFs and IOP measurements
extracted from the electronic medical records of 5 region-
ally different glaucoma clinics in England. A total of 205
eyes with diagnosis of uveitis plus glaucoma were
compared with 4600 eyes with POAG only. Minimum in-
clusion criteria were ‡4 visits within a 4-year window.
Relative risk (RR) of being a ‘‘rapid progressor’’ (mean
deviation [MD] loss ‡1.5 dB/year) was calculated. A
mixed-effects model (MEM) and a pointwise VF progres-
sion analysis of pattern deviation were used to confirm
differences between the groups. Longitudinal IOP
mean, range, and variability were compared with rate of
VF progression.
 RESULTS: Median (interquartile range) baseline MD in
the uveitis and POAG groups was L3.8 (L8.7, L1.5)
dB andL3.1 (L6.6,L1.2) dB, respectively. The uveitis
and POAG groups had 23 of 205 (11%) and 331 of
4600 (7%) ‘‘rapidly progressing’’ eyes, respectively. Age-
adjusted RR for ‘‘rapid progression’’ in uveitic vs POAG
eyes was 1.9 (95% confidence interval: 1.8-2.0). The
MEMconfirmed that uveitic eyes (L0.49 dB/year) showed
higher rates of VF progression than the POAG group
(L0.37 dB/year; P < .01). IOP range and variability
were higher in the ‘‘rapidly progressing’’ uveitic eyes.upplemental Material available at AJO.com.
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© 2019 THE AUTHOR(S). PU CONCLUSIONS: Our analysis suggests that VF loss oc-
curs faster in glaucoma patients with uveitis than those
without uveitis. The risk of progressing rapidly in glau-
coma with uveitis is almost double than in those without
uveitis. Early identification of ‘‘rapid progressors’’ may
enable targeted intervention to preserve visual function
in this high-risk group. (Am J Ophthalmol 2019;207:
144–150.  2019 The Author(s). Published by
Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).)
U
VEITIS REMAINS THE FOURTH MOST COMMON
cause of blindness in the working-age population
throughout the developed world, with visual
impairment affecting between 2.8% and 10% of uveitic pa-
tients.1–4 Reduced visual function may result from direct
damage to uveal tract structures, but more commonly
occurs owing to secondary tissue damage, with the most
prevalent complications being cataract, macular edema,
and glaucoma.5 Of these, both cataract and macular edema
can be considered at least partially reversible; however, vi-
sual impairment owing to glaucoma is irreversible and thus
early diagnosis and appropriate management of uveitic
glaucoma is of paramount importance.
Glaucoma in the presence of uveitis can develop via a
number of mechanisms.6 Increases in intraocular pressure
(IOP) can occur owing to mechanical obstruction of
aqueous outflow, presenting with secondary angle closure
owing to pupillary block from posterior synechiae, or
more chronically following development of peripheral
anterior synechiae or angle rubeosis. Secondary open-
angle glaucoma may develop owing to chronic inflamma-
tory damage to the trabecular meshwork, or in response
to corticosteroid therapy. In addition, specific uveitis en-
tities are associated with elevation of IOP, such as
Posner-Schlossmann syndrome, Fuchs heterochromic
iridocyclitis, and herpetic uveitis. Active inflammation,
corticosteroid usage, increasing age, and number of years
since diagnosis have each been demonstrated to be associ-
ated with raised IOP in uveitic patients.7
The prevalence of raised IOP in uveitis remains poorly
defined, since increases in IOP may be transient and may
not progress to true glaucomatous optic neuropathy. The
prevalence of treated glaucoma varies from 20% to
30% in most cohorts.5,7–9 Accurate stratification of0002-9394
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patients at risk of uveitic glaucoma is necessary to identify
those at high risk of irreversible vision loss. Intensive
monitoring and active intervention are important to
prevent irreversible visual impairment in these patients.10
With the widespread adoption of electronic medical re-
cords (EMR), it is now possible to collect clinical data from
large patient populations, identifying trends in disease pro-
gression and treatment response that have not been
possible with traditional paper-based records. Such ‘‘Big
Data’’ approaches have been successfully used to charac-
terize the population and predict outcomes in other
ophthalmic diseases.11–15 This study aims to use large-
scale EMR data for comparing the rate of visual field
(VF) loss in uveitis patients with glaucoma, compared to
those with primary open-angle glaucoma (POAG), and
explore whether this is associated with IOP.METHODS
ANONYMIZED RECORDED DATA BETWEEN APRIL 2000 AND
March 2015 were extracted from the Medisoft (Medisoft
Ltd, Leeds, UK) EMR from 5 regionally different glaucoma
clinics in England and linked to the Royal College of Oph-
thalmologists’ National Ophthalmology Database.16 The
data used were collected for a Healthcare Quality Improve-
ment Partnership project conducted by the Royal College
of Ophthalmologists (National Ophthalmology Database
Audit provider) as part of the National Clinical Audit
and Patient Outcomes Programme. The study adhered to
the Declaration of Helsinki and all analyses of the data
were approved by a research ethics committee of City, Uni-
versity of London. All patient data were anonymized and
securely held on the university database. The resulting
database contained records from 71 404 patients.
 INCLUSION CRITERIA: Eyes were sorted into 2 groups
based on EMR diagnostic labeling: a POAG group and a
group of patients with both a ‘‘uveitis’’ and ‘‘glaucoma’’
diagnosis. POAG was defined by having a diagnostic label
of ‘‘POAG’’ or ‘‘chronic open-angle glaucoma (COAG)’’
without any uveitis co-pathologies. Uveitis plus glaucoma
was defined as having both a label of POAG or COAG
plus a uveitis label. A variety of anatomic and disease-
specific labels for uveitis were included (a full list of diag-
nostic labels are provided in the Appendix A; Supple-
mental Material available at AJO.com). Initial extraction
by diagnosis found 1179 eyes with uveitic glaucoma and
21 209 eyes with POAG (Figure 1). The inclusion criteria
for each eye were a minimum of 4 VF tests over 4 years,
with at least 4 of the included tests being performed within
the initial 4 years (Figure 2). Only VFs from the Humphrey
Field Analyzer (HFA) using Goldmann size III (white-on-
white) stimuli with the 24-2 test pattern acquired withVOL. 207 EVALUATING THE IMPACT OF UVeither SITA Standard or SITA Fast testing algorithms
were included.
A secondary analysis on the association between IOP
behavior and VF progression was also carried out. In addi-
tion to the above inclusion criteria, a minimum of 4 IOP
measurements in the first 4 years were needed.
 STATISTICAL ANALYSIS: Analysis was carried out on 1
eye per patient; if a patient had 2 eligible eyes, 1 was chosen
at random. The first VF examination of each series was
defined as the baseline measurement. HFA pointwise sensi-
tivity values and mean deviation (MD; an estimate of
average VF sensitivity relative to healthy age-matched
controls) values were extracted for each VF for each eye.
Pattern deviation (PD) pointwise values were calculated
using the visualFields package in R.17
Ordinary least-squares (OLS) linear regression ofMD over
time was used to estimate rates of progression (dB/year). As
with previous studies, a fast-progressing VF series was defined
as having a rate of progression slope of >_1.5 dB/year.13,18 A
crude relative risk (RR) was calculated as the ratio of the
proportion of fast progressors in the uveitis and POAG
groups, for each10-year age group from40 to100years, as esti-
mated by the OLS regression slopes. An overall age-adjusted
RR was calculated using the direct method.19
Two secondary VF progression analyses were also
performed. First, a linear mixed-effects model analysis,
which can estimate the regression coefficient while
including both fixed and random effects, was fitted.20 MD
was treated as a response variable; time (years since first
visit), group (POAG or uveitis), and baseline age were
treated as fixed effects and individuals as a random effect
(model provided in Appendix B, available at AJO.com).
Second, the permutation of pointwise linear regression
(PoPLR) technique was used to analyze the pointwise sensi-
tivities and PD values of each VF series.21–23 PoPLR
repeatedly permutes the order of VF visits in a series to
give robust estimations of the likelihood of significant VF
change. In our case PoPLR was performed on PD values as
an indicator of worsening VF to mitigate global changes
that may occur, for example, from developing cataract.
The outcome of interest is simply the proportion of eyes
showing statistically significant progression (at P ¼ .05) in
the uveitic and POAG groups (R code for the PoPLR
analysis is provided in Appendix C; Supplemental Material
available at AJO.com).
IOP data were analyzed using longitudinal metrics:
mean, range, and mean absolute error (MAE). Mean IOP
was defined as the mean of all recorded IOP values in the
series. IOP range was defined as the highest value (peak)
minus the lowest value (trough) in the IOP series. MAE,
as a measure of IOP variability, was estimated by fitting
an OLS linear regression to IOP values over time, then
extracting errors (predicted values minus the observed
IOP) at each visit. The mean of the absolute values of these
errors was theMAE value. Univariate associations between145EITIS ON VISUAL FIELD LOSS
FIGURE 1. Flow chart showing the inclusion criteria leading to a study sample of 4600 primary open-angle glaucoma (POAG) eyes
and 205 uveitisD glaucoma (UG) eyes for the visual field (VF) analysis and 3386 POAG eyes and 143 UG eyes for the intraocular
pressure (IOP) analysis. Number of ‘‘fast progressors’’ in the VF analysis are also shown. Center 4 is highlighted in red as it was
missing a large amount of diagnosis data.rates of progression and IOP metrics were analyzed.
vStatistical comparisons were made using the Mann-
Whitney U test.
Analysis was varied out using R (R Development Core
Team, R Foundation for Statistical Computing, Vienna,
Austria).RESULTS
 BASELINE CHARACTERISTICS: From a starting popula-
tion of 1179 eyes, 205 (17%) eyes with uveitis plus glau-
coma satisfied the inclusion criteria and were included in
further analysis. From a starting population of 21 209
eyes, 4600 (22%) eyes with POAGwere included in further
analysis (Figure 2). Median (interquartile range [IQR]) age
of the patients was 64 (53, 73) and 70 (62, 76) years in the
uveitis and POAG groups, respectively. Baseline MD
model estimates in the uveitis and POAG groups were
-5.55 (95% confidence interval [CI]: -6.39, -4.47) dB and
-4.47 (95% CI: -4.31, -4.63) dB, respectively. Median146 AMERICAN JOURNAL OF(IQR) intensity (frequency) of VF testing was the same,
with an interval of 10 months between each VF test, for
both groups.
 RATE OF VISUAL FIELD LOSS: The uveitis and POAG
groups had 23 of 205 (11%) and 331 of 4600 (7%) eyes
that progressed at >_1.5 dB/year, respectively. The crude
RR of a fast rate of progression for uveitis/POAG was 1.6
(95% CI: 1.1-2.3) and age-adjusted RR was 1.9 (95% CI:
1.8-2.0). This indicates that, for a similarly aged popula-
tion, a patient in the uveitis group was 1.9 times more likely
to be a fast progressor than patients in the POAG group.
Further analysis using the mixed-effects model showed
that the age-adjusted rate of progression was -0.49 dB/
year for the uveitis group and -0.37 dB/year for the
POAG group. The estimated average age-corrected differ-
ence in rate of progression between the groups at the mean
age was -0.12 dB/year (P < .01).
VF progression analysis using PoPLR on PD values indi-
cates that the uveitis group has a higher proportion of
significantly progressing eyes (21.2%), compared to the
POAG group (18.5%).NOVEMBER 2019OPHTHALMOLOGY
FIGURE 2. A schematic illustrating the visual field (VF) series
inclusion criteria and method for calculating rates of mean devi-
ation loss (dB/year) for 2 example eyes. Eyes were excluded if
<4 VF examinations or<4 years of follow-up. Rates of VF
loss were calculated from ordinary least squares linear regres-
sion of the baseline VF and the series of examinations that fell
within a 4-year period after it (white window). In the top
example, the 5th, 6th, and 7th recorded VFs fall outside of
the window and were not used in the calculation. In the bottom
example, only the seventh examination was excluded. This en-
sures that all rates are estimated with equivalent precision,
allowing for comparisons over time. LONGITUDINAL INTRAOCULAR PRESSURE ANALYSIS:
A total of 143 eyes with uveitis plus glaucoma and 3386
eyes with POAG met the additional inclusion criteria for
longitudinal IOP analysis. A summary of longitudinal
IOP measurements can be found in the Table. We did
not find a statistically significant difference in mean IOP
(within 1 mm Hg) between the 2 groups, yet there was
wider range and higher MAE in the uveitis group
(P < .001). A comparison between fast and nonfast
progressors found the mean IOP difference to be within
1 mm Hg for all groups. IOP range was wider in the fast
progressors of both POAG and uveitis groups (both
P < .05), and widest in the fast-progressing uveitis group
(21 mmHg). Similarly, MAE was higher in fast progressors
of both diseases (P < .01), but highest in the fast-
progressing uveitis group (3.5 mm Hg).DISCUSSION
THIS IS THE FIRST STUDYTOUSE REAL-WORLD EMRDATATO
compare rates of VF loss in uveitis patients with glaucoma
and those with POAG.We have demonstrated that uveitis
patients with a diagnosis of glaucoma were likely to be
younger and have a worse MD at baseline than those
with a diagnosis of POAG. The uveitis group were more
likely to lose VF at a rapid rate (>_1.5 dB/year loss in MD)
compared with the POAG group, with an age-adjusted
RR of 1.9 (95% CI: 1.8-2.0). Despite this, our data show
that the average frequency of VF monitoring is the sameVOL. 207 EVALUATING THE IMPACT OF UVfor both diseases. Our longitudinal IOP analysis suggests
IOP range and variability had a stronger association with
rapid VF loss than mean IOP.
Our findings suggest that patients with a combination of
uveitis and glaucoma lose vision more rapidly than POAG,
yet on average they are monitored with VFs at the same in-
tensity. Our estimate of rate of VF loss in POAG (-0.37 dB/
year) is higher than has previously been reported in the
literature; however, our estimates differ in that they were
adjusted for age.13,24 The observed proportion of fast
progressors in our POAG cohort is also similar to
previous studies: defined thresholds for ‘‘fast’’ or ‘‘rapid’’
progression in published literature range from >_1 to 2 dB/
year loss in MD, and reported prevalence of patients
progressing rapidly varies between 3% and 17% in
previous studies.24–29
The main strength of our study is the large starting sam-
ple size compared to others in the literature. Although only
205 uveitic eyes were included in our final VF progression
analysis, a sufficiently large starting sample was required
to reach the final 205 included samples. We restricted
the inclusion of patients to those with a minimum of 4
VF tests over at least 4 years. Additionally, at least 4 of
the included VF tests must have been performed within 4
years of the first test. As with our previous work, the min-
imum inclusion criteria was a compromise between maxi-
mizing sample size while still ensuring robustness of our
rate of progression estimates.13,15
Our study also has several limitations. Firstly, our data
were reliant upon accurate recording in the EMR. Diag-
nostic labeling within the Medisoft EMR is not a manda-
tory field and can be entered as free text, or not entered
at all. We included a large list of diagnostic labels
commonly found in the presence of uveitis to widen our
capture of uveitis subjects. However, a large portion of uve-
itis subjects in this analysis were lacking in anatomic or
disease-specific diagnostic labels in the EMR, thus limiting
our ability to explore patterns in specific uveitis subtypes.
We took steps in our analyses to mitigate the confounding
effects of ocular comorbidities. For example, PoPLR VF
progression analysis with PD values is designed to identify
localized VF change and not just general reduction in VF
sensitivity that might be attributed to developing cataract.
Results from the PoPLR analysis supported our main find-
ings. Nevertheless, we cannot fully account for the effects
of ocular comorbidities on perimetric performance of the
patients. Uveitic patients are susceptible to a range of com-
plications such as cataract, cystoid macular edema, fibrin
deposition, band keratopathy, and epiretinal membrane,
all of which may affect VF performance. Acute inflamma-
tory processes may cause temporary drops in visual acuity,
which subsequently resolves. This may explain why some
patients’ MD seems to improve over time (ie, perhaps
owing to cataract surgery or resolution of inflammatory dis-
ease such as cystoid macular edema), although this could
also be attributed to patient variability and learning147EITIS ON VISUAL FIELD LOSS
TABLE. Longitudinal Intraocular Pressure Metrics: Comparison Between Primary Open-Angle Glaucoma and Uveitis Plus Glaucoma
Groups
IOP (mm Hg), Median (IQR) POAG (N ¼ 3386) Uveitis Plus Glaucoma (N ¼ 143)
Mean 16.5 (14.5, 18.8) 15.9 (13.5, 19.3) P ¼ .445
Range 10.5 (7.0, 15.0) 13.3 (8.0, 23.5) P < .001*
Mean absolute error 2.1 (1.6, 2.8) 2.6 (1.9, 4.4) P < .001*
Normal Progressors Rapid Progressors Normal Progressors Rapid Progressors
Mean 16.6 (14.6, 18.6) 16.0 (13.7, 17.9) P < .001* 15.9 (12.6, 19.2) 16.4 (12.1, 21.0) P ¼ .827
Range 10.0 (7.0, 15.0) 12.0 (8.5, 17.0) P < .001* 13.0 (8.0, 22.0) 21.0 (12.0, 30.8) P ¼ .040*
Mean absolute error 2.1 (1.6, 2.8) 2.3 (1.7, 3.2) P < .001* 2.6 (1.8, 2.9) 3.5 (2.3, 6.1) P ¼ .051
Statistically significant P values are indicated by an asterisk (*).
IOP ¼ intraocular pressure; IQR ¼ interquartile range; POAG ¼ primary open-angle glaucoma.effect.30–32 On the other hand, progressive loss of visual
acuity from longstanding uveitic damage (such as scarring
and retinal atrophy) may also confound the apparent loss
of MD in the uveitic group. Structural information such
as retinal nerve fiber layer thickness, cup-to-disc ratio, or
the inclusion of imaging data would be useful for differen-
tiating between true glaucomatous VF loss and global loss
owing to other causes. Although not available in this data-
set, linkage of structural information would be of interest
for future studies.
An important finding is the worse presenting MD in the
uveitic group, suggesting early VF loss may be under-
detected. Additionally, the baseline age in the uveitis
plus glaucoma group was younger, which also supports
the hypothesis that uveitic glaucoma may progress faster.
Detecting early VF loss is clinically difficult if perimetric
testing is not performed routinely, particularly in the
absence of a deranged IOP. In the context of uveitis, con-
trolling the inflammation may require more clinical ur-
gency and early glaucomatous damage can be easily
overlooked. On the other hand, anti-inflammatory treat-
ment, of which corticosteroids are the preferred first-line
agent, can precipitate raised IOP in up to a third of pa-
tients.33,34 Steroid implants have been shown to increase
the risk of developing glaucomatous optic neuropathy by
4 times compared to those taking systemic therapy.35 A
comparison of VF progression in uveitis patients receiving
steroid treatment vs those without would be of interest for
future studies. Such an analysis would require accurate data
on frequency, duration, and formulation of steroid use,
which is not routinely captured by the Medisoft EMR. Suc-
cessful management of glaucoma in uveitis requires simul-
taneous treatment of inflammation and IOP elevation. In
some cases, controlling the inflammation also helps to
reduce IOP and there is evidence to suggest those treated
with aggressive anti-inflammatory therapy have better out-
comes.6 Antiglaucomatous drugs such as beta-blockers and
carbonic anhydrase inhibitors can be used to lower the IOP.148 AMERICAN JOURNAL OFSome controversy exists around the use of prostaglandin
analogues (PGAs) as a first-line agent owing to the theoret-
ical risk of blood-aqueous barrier disruption and cystoid
macular edema; however, multiple studies have found no
differences in the rate of inflammatory recurrences and it
is considered safe to use PGAs as first-line therapy in quies-
cent uveitis.36,37 The management options for glaucoma in
uveitis are predominantly with an aim to decrease IOP, but
it is unclear whether these treatments influence IOP
variability.
The exact pathologic process behind glaucoma in
different uveitic subtypes is difficult to define, as there are
often multiple coexisting mechanisms driving IOP changes
and glaucomatous damage. Yet, elevated IOP has been
considered the main modifiable risk factor. Our study,
albeit based on retrospective data, represents the largest
published longitudinal analysis of IOP behavior in uveitis
patients with glaucoma. We found the mean longitudinal
IOP to be similar in uveitis and POAG. However, IOP
range and MAE were higher in uveitis patients. In both
uveitic and POAG groups, IOP range and MAE are consis-
tently higher in those progressing rapidly compared to
those losing less than 1.5 dB/year in MD. It is unclear
whether the fluctuant IOP is a contributing factor to glau-
comatous damage, or whether it is simply a more prevalent
finding in those with more severe glaucoma, representing
those with the poorest controlled IOP and therefore
receiving the most aggressive treatment. The published
literature on POAG is inconsistent in this area, with
some studies reporting a strong relationship between ocular
hypertension and glaucomatous field loss, while others sug-
gest that long-term IOP variability is associated more
strongly with progression than mean IOP.38,39 Lee and
associates suggest a 1 mm Hg increase in standard
deviation of IOP is associated with a 4-fold increase in
risk of POAG progression.40 In uveitis, published long-
term data on IOP is limited and understanding of IOP
behavior in the context of inflammation, secondaryNOVEMBER 2019OPHTHALMOLOGY
structural damage, and anti-inflammatory treatment re-
mains poor.
Glaucoma secondary to uveitis is an important cause of
irreversible sight loss, which is challenging to detect and
manage. Our main finding from retrospective analysis of
clinical data from multicenter glaucoma services in En-
gland shows that uveitis patients with glaucoma are almost
twice as likely to lose VF rapidly when compared to pa-
tients with POAG. Therefore, clinicians managing pa-
tients with uveitis should remain vigilant for
glaucomatous damage in these high-risk patients. InVOL. 207 EVALUATING THE IMPACT OF UVEngland, there is evidence that most patients get a similar
diet of VF examinations during follow-up, and our findings
support this.13,18 Our results at least highlight that uveitis
patients require closer attention in order to rule out rapid
loss of VF during treatment. IOP variability is more
common in uveitic eyes and our findings suggest that IOP
fluctuates across a wider range in this group than in
POAG. We suggest a low threshold for glaucoma
screening in patients with uveitis, even if IOP is within
normal limits and particularly in the presence of a
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